Moleculera Labs Inc. is an Oklahoma City-based developer of tests for autoimmune neurologic conditions in children and adults. The company has developed the Cunningham Panel, a series of tests that predicts a patient’s likelihood of having Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococci (PANDAS). The article notes PANDAS are treatable neurologic conditions that may be associated with motor tics and obsessive compulsive disorders (OCD), which are often associated with Autism Spectrum Disorders. Moleculera is led by co-founder and Chief Executive Officer Dr. Craig Shimasaki. On May 20, 2015, the company raised $1.06m in funding to expand development of its tests. The round was led by i2E Inc., which committed $530k through its Accelerate Oklahoma! Fund, with participation from SeedStep Angels ($225k) and other investors. Moleculera Labs has developed the Cunningham Panel, a series of tests that predict a patient’s likelihood of having PANDAS. The panel was developed by co‑founder and CSO Madeleine Cunningham, a professor at the University of Oklahoma Health Sciences Center. The company says PANDAS are treatable neurologic conditions that can be associated with motor tics, obsessive compulsive disorder and often with Autism Spectrum Disorders. Moleculera intends to use newly raised funds to expand its services. The company was founded in 2011 and is based in Oklahoma City. Leadership includes Co‑Founder and CEO Dr. Craig Shimasaki and co‑founder Madeleine Cunningham, Ph.D.

Total raised

$3M

Funding rounds

2

Latest round

Equity

Latest activity

May 2015